clinical trial · NCT04455633
Efficacy, Safety, and PK of LX9211 in Participants With Diabetic Peripheral Neuropathic Pain
Diabetic Peripheral NeuropathyDiabetesLX9211LX9211 Matching Placebo
brief summary
Evaluation of the efficacy of a low and high dose of LX9211 compared to placebo in reducing pain related to diabetic peripheral neuropathy (DPNP) over an 11 week assessment period.
started
Sep 3, 2020
primary completion
May 23, 2022
completion
Jun 28, 2022
last updated
Jun 25, 2025
official title
A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of LX9211 in the Treatment of Diabetic Peripheral Neuropathic Pain
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol